Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-03-28
2006-03-28
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S117000, C544S279000, C544S317000, C544S318000, C514S264110
Reexamination Certificate
active
07019002
ABSTRACT:
The invention provides pyrido[2,3-d]pyrimidin-7(8H)-one telomerase inhibitors of the formulawhere R1, R2 are as defined herein. The invention also provides methods for preparing the compounds of formula I, methods of using the compounds to treat diseases such as cancer, and pharmaceutical compositions comprising the compounds.
REFERENCES:
patent: 6242452 (2001-06-01), Ogino et al.
Incles et al, Current Opinion in Investigational Drugs. 2003 Jun.; 4(6):675-85.
Rudolph, Cell, vol. 96, 701-712, Mar. 5, 1999.
Titia de Lange et al, “For Better or Worse? Telomerase Inhibition and Cancer”(Cell, vol. 98, 273-275, Aug. 6, 1999), p. 274.
Asai, Cancer Res. 63(14), 3931-9, Jul. 15, 2003.
SCIFINDER printout for compound with registry No. 64224-21-1.
SCIFINDER printout for compound with registry No. 797791-98-1.
Herbert, et al., “Inhibition of Human Telomerase in Immortal Human Cells Leads to Progressive Telomere Shortening and Cell Death”, PNAS, vol. 96, No. 25, pp. 14276-14281, Dec. 1999.
Hahn, et al., “Inhibition of Telomerase Limits the Growth of Human Cancer Cells”, Nature Medicine, vol. 5, No. 10, pp. 1164-1170, Oct., 1999.
Nakamura, et al., “Correlation of Telomere Lengths in Normal and Cancers Tissue in the Large Bowel”, Cancer Letters, 158, pp. 179-184, 2000.
Shay, et al., “A Survey of Telomerase Activity in Human Cancer”, European Journal of Cancer, vol. 33, No. 5, pp. 787-791, 1997.
Blackburn, “Telomerases”, Annu. Rev. Biochem.,61:113-29, 1992.
Shammas, et al., “Telomerase Inhibition by Peptide Nucleic Acids Reverses ‘Immorality’ of Transformed Human Cells”, Oncogene, 18, pp. 6191-6200, 1999.
Feng, et al., “The RNA Component of Human Telomerase”, Science, vol. 269, pp. 1236-1241, 1995.
Harley, “Telomere loss: mitotic clock or genetic time bomb?”, Mutation Research, vol. 256, pp. 271-282, 1991.
Angiolini Mauro
Ballinari Dario
Bassini Domenico Fusar
Bonomini Luisella
Gude Markus
Berch Mark L.
Pharmacia & Upjohn S.p.A.
Smolizza Christian M.
Zelson Steve T.
LandOfFree
Pyridopyrimidinones derivatives as telomerase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyridopyrimidinones derivatives as telomerase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridopyrimidinones derivatives as telomerase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3526672